ライフサイエンスコーパス: immunocompromised

1 therapy (ART) when they are already severely immunocompromised.

2 a major health concern for patients who are immunocompromised.

3 Most infected persons were immunocompromised.

4 rldwide and are pervasive concerns among the immunocompromised.

5 tus invasive infections primarily affect the immunocompromised.

6 nless the patient was clinically unstable or immunocompromised.

7 es were compared between immunocompetent and immunocompromised.

8 rrhea and abdominal pain were more common in immunocompromised.

9 ilitating infection that can be fatal in the immunocompromised.

10 atient, regardless of whether the patient is immunocompromised.

11 e in significantly more immunocompetent than immunocompromised (40.7% vs. 12.9%, p = 0.002).

12 We pre-exposed immunocompetent C57BL/6 and immunocompromised A129 or IFNAR mice to wild-type CHIKV,

13 The immunocompromised adult population with haematological m

14 s introduced for US children in 2010 and for immunocompromised adults >=19 years old in series with t

15 ntroduced for U.S. children in 2010, and for immunocompromised adults >=19 years old in series with t

16 he risk of any HZ complication was higher in immunocompromised adults (IRR, 3.6 [95% CI, 3.5-3.7]) an

17 he risk of any HZ complication was higher in immunocompromised adults (IRR=3.6, 95%CI 3.5-3.7) and hi

18 Immunocompromised adults accounted for 13% of these case

19 ble for a variety of devastating sequelae in immunocompromised adults and in developing fetuses.

20 Immunocompromised adults are at .increased risk of herpe

21 Immunocompromised adults are at increased risk of herpes

22 risk of hospital-attended HZ was higher for immunocompromised adults compared with immunocompetent (

23 risk of hospital-attended HZ was higher for immunocompromised adults compared with immunocompetent a

24 nic to humans, especially young children and immunocompromised adults.

25 morbidity and mortality, particularly among immunocompromised and at-risk individuals.

26 Ruxolitinib-treated tumors in both the immunocompromised and immunocompetent animal models demo

27 ost commonly used in HNC research, including immunocompromised and immunocompetent animals.

28 re of increasing incidence and importance in immunocompromised and immunocompetent patients.

29 major cause of morbidity and mortality among immunocompromised and immunonaive individuals.

30 Patients with cancer are immunocompromised and may be vulnerable to COVID-related

31 dmitted to the intensive care unit, 48% were immunocompromised, and 45% had underlying urologic abnor

32 patients were admitted to the ICU, 47% were immunocompromised, and 46% of patients had underlying ur

33 tial morbidity and mortality in infants, the immunocompromised, and older adults.

34 7.4 +/- 5.8 years; 46% were female; 18% were immunocompromised; and 51% demonstrated chronic comorbid

35 Xenotransplantation of human skin onto immunocompromised animals can overcome this limitation o

36 s, often resulting in mortality of young and immunocompromised animals.

37 glected condition that places people who are immunocompromised at risk of hyperinfection and death.

38 Patients who are immunocompromised because of malignancy have an increase

39 a chronic case of influenza B in a severely immunocompromised child we infer an N(e) of 2.5 x 10(7)

40 improved diagnostics, pulmonary pathogens in immunocompromised children frequently evade detection, l

41 longitudinally collected blood samples from immunocompromised children to show that the observations

42 ected 41 lower respiratory specimens from 34 immunocompromised children undergoing evaluation for pul

43 nificant inoculation of the lower airways of immunocompromised children with diverse bacteria, fungi,

44 ificance of outlier microbes in the lungs of immunocompromised children with pulmonary disease.

45 dentifying diverse pathogens in the lungs of immunocompromised children.

46 Household contacts to COVID-19 patients with immunocompromised conditions had increased odds of infec

47 sion of cell-mediated immune responses under immunocompromised conditions may facilitate the establis

48 Under immunocompromised conditions, EBV can trigger human canc

49 set of type I interferon signaling-deficient immunocompromised dams.

50 ength of stay compared with patients without immunocompromised diagnoses (p < 0.001).

51 Immunocompromised diagnoses are present in 28% of childr

52 rtality among centers despite adjustment for immunocompromised diagnoses, known risk factors for seps

53 PICU resource utilization varied by immunocompromised diagnosis and history of hematopoietic

54 shock; 3,021 of these patients (28%) had an immunocompromised diagnosis.

55 Significantly more immunocompetent than immunocompromised did not receive any specific therapy (

56 Among them, 305 (38%) were immunocompromised, distributed into solid tumors (122),

57 ularly in vulnerable populations such as the immunocompromised, elderly, and young.

58 migrants and 4.8% (95% CI, 1.5-14.3%) among immunocompromised groups.

59 of 126 children who had virus genotyping (2 immunocompromised) had varicella (n = 2) or zoster (n =

60 to demonstrate chronic viral shedding by an immunocompromised, hospital-acquired case patient.

61 nslocation across the intestinal tract in an immunocompromised host is substantially reduced after ph

62 us infection is an emerging challenge in the immunocompromised host, in whom it may be asymptomatic o

63 ts into the evolution of norovirus within an immunocompromised host.

64 tely evaluate the sensitivity of QFT-Plus in immunocompromised hosts and children.

65 Transplant recipients and other immunocompromised hosts are at particular risk for devel

66 especially among recently exposed contacts, immunocompromised hosts, and young children.

67 ey could serve as opportunistic pathogens in immunocompromised hosts.

68 lytic replication that can be pathogenic in immunocompromised hosts.

69 ibuted deep mycosis that affects healthy and immunocompromised hosts.

70 ly presents as an opportunistic infection in immunocompromised hosts.

71 ociated with numerous cancers, especially in immunocompromised hosts.

72 and the following cytokine storm.IMPORTANCE Immunocompromised human patients can develop severe, oft

73 nd remain highly sensitive to pegIFNalpha in immunocompromised humanized mice.

74 [P], age [A], depressed renal function [D], immunocompromised [I], and procedure type [T]) with an o

75 Hospitalized immunocompromised (IC) adults with influenza may have wo

76 from the upper respiratory tract of a female immunocompromised individual with chronic lymphocytic le

77 ophthalmicus occurs primarily in elderly or immunocompromised individuals after reactivation of vari

78 asles virus (MeV) infection can be severe in immunocompromised individuals and lead to complications,

79 al pathogens that cause severe infections in immunocompromised individuals and patients with cystic f

80 scence can cause life-threatening disease in immunocompromised individuals and recurrent ocular lesio

81 Pediatric and immunocompromised individuals are at particular risk for

82 omegaloviruses are betaherpesviruses that in immunocompromised individuals can lead to severe patholo

83 atric cohorts or in a therapeutic setting in immunocompromised individuals in conjugation with existi

84 Our data indicate that certain immunocompromised individuals may shed infectious virus

85 ida albicans can cause systemic infection in immunocompromised individuals that is associated with a

86 pectancy has increased, so has the number of immunocompromised individuals who receive prolonged trea

87 use of infectious morbidity and mortality in immunocompromised individuals, although the relationship

88 causes congenital birth defects, disease in immunocompromised individuals, and blindness.

89 of the disease is often fatal, especially in immunocompromised individuals, as reflected by the high

90 In immunocompromised individuals, Aspergillus conidia can g

91 In debilitated and immunocompromised individuals, C. albicans may spread to

92 t of multiple malignancies, predominantly in immunocompromised individuals, including HIV/AIDS patien

93 ction causes severe disease and mortality in immunocompromised individuals, including organ transplan

94 major pathogen in congenitally infected and immunocompromised individuals, where multiple-strain inf

95 cause severe inflammatory organ diseases in immunocompromised individuals.

96 se 1.6 million deaths annually, primarily in immunocompromised individuals.

97 t causes fatal meningoencephalitis in mostly immunocompromised individuals.

98 cause life-threatening systemic infection in immunocompromised individuals.

99 on on coronavirus disease 2019 (COVID-19) in immunocompromised individuals.

100 congenital infection and a major pathogen in immunocompromised individuals.

101 EBV-seropositive HLA-B*07:02(+) healthy and immunocompromised individuals.

102 sociated with encephalitis and meningitis in immunocompromised individuals.

103 attii are an important cause of mortality in immunocompromised individuals.

104 is mycobacteria and are pathogenic mainly in immunocompromised individuals.

105 l reactivation can cause severe pathology in immunocompromised individuals.

106 different types of malignancies, usually in immunocompromised individuals.

107 een linked to severe diseases, especially in immunocompromised individuals.

108 eing reactivated, causes serious diseases in immunocompromised individuals.

109 cted patients, especially young children and immunocompromised individuals.

110 n produce neurological damage in fetuses and immunocompromised individuals.

111 cers and remains a leading cause of death in immunocompromised individuals.

112 pathogen that causes significant disease in immunocompromised individuals.

113 pathogens in individuals with AIDS and other immunocompromised individuals.

114 the MCC incidence increases among aging and immunocompromised individuals.

115 es on the lives of malnourished children and immunocompromised individuals.

116 ial infections, posing a significant risk in immunocompromised individuals.

117 spergillosis causes substantial mortality in immunocompromised individuals.

118 ently fatal lung disease primarily affecting immunocompromised individuals.

119 so cause severe complications in elderly and immunocompromised individuals.

120 galovirus (HCMV), a significant pathogen for immunocompromised individuals.

121 ith particularly grave impact on infants and immunocompromised individuals.

122 ed with endothelial Kaposi's sarcoma (KS) in immunocompromised individuals.

123 le of causing infections in both healthy and immunocompromised individuals.

124 population and can be fatal in neonatal and immunocompromised individuals.

125 adoptive immunotherapy for the treatment of immunocompromised individuals.

126 infection that can be fatal in neonatal and immunocompromised individuals.

127 uccessfully administered to small cohorts of immunocompromised individuals; initial trials showed eff

128 ted wild-type mice with MuAstV isolated from immunocompromised mice and found that the virus was dete

129 rbon (PFC) emulsion ex vivo and infused into immunocompromised mice bearing subcutaneous human U87 gl

130 identifies drugs performing well not only in immunocompromised mice but also in the presence of spont

131 ombination, nor the xenograft environment in immunocompromised mice efficiently support the expansion

132 e models such as the human skin xenograft on immunocompromised mice might be used in bacterial skin i

133 Similarly, following transplantation into immunocompromised mice the percentage of multipotent HSP

134 Finding that immunocompromised mice were resistant to human astroviru

135 Immunocompromised mice were transplanted with pancreatic

136 Immunocompromised mice with melanomas derived from patie

137 Through use of immunocompromised mice with transgenic expression of hum

138 d by their capacity to initiate leukaemia in immunocompromised mice(4).

139 acked the ability to engraft successfully in immunocompromised mice, but IDH1 overexpression in these

140 on-specific organoids were transplanted into immunocompromised mice, duodenum-like organoids and ileu

141 safe since it is unable to cause disease in immunocompromised mice, induces robust host protection a

142 When xenografted into immunocompromised mice, RB1 mutant cells exhibit an elev

143 vivo using an orthotopic xenograft model in immunocompromised mice.

144 e directed invasion of xenografted tumors in immunocompromised mice.

145 cells are critical to sexual transmission in immunocompromised mice.

146 s and Helicobacter typhlonius, isolated from immunocompromised mice.

147 sulting in a self-limiting infection even in immunocompromised mice.

148 ilayer model and in the lungs of neutropenic immunocompromised mice.

149 etic reconstitution for at least 24 weeks in immunocompromised mice.

150 fer protection against M. avium infection in immunocompromised mice.

151 transplantation under the kidney capsule of immunocompromised mice.

152 vessel outgrowth prior to implantation into immunocompromised mice.

153 MK1/2 shRNA were implanted intracranially in immunocompromised mice.

154 ochemical and phenotypic abnormalities in an immunocompromised mouse model of Mucopolysaccharidosis t

155 ection was horizontally transferable between immunocompromised mouse strains by co-housing and fecal

156 two distinct viruses isolated from different immunocompromised mouse strains, we observed virus strai

157 sal infection in several immunocompetent and immunocompromised mouse strains.

158 at high doses, BPZE1 is safe in the severely immunocompromised MyD88-deficient mice, whereas virulent

159 ing six validated HGSC cell lines, in highly immunocompromised NSG mice by varying the injection site

160 6 in adults >=18 years of age categorized as immunocompromised or immunocompetent.

161 31, 2016 in adults >=18 years categorized as immunocompromised or immunocompetent.

162 HCMV can cause severe multiorgan disease in immunocompromised or immunonaive patients.

163 using significant morbidity and mortality in immunocompromised or transplant patients.

164 ous cell carcinomas (cSCCs), particularly in immunocompromised organ transplant recipients (OTRs).

165 lation of low CrAg titers with disease in an immunocompromised patient population.

166 Notably, one immunocompromised patient with confirmed SARS-CoV-2 infe

167 but not curative effect of remdesivir in an immunocompromised patient.

168 n and reactivation of a past infection in an immunocompromised patient.

169 analysis of intrahost HSV-1 evolution in an immunocompromised patient.

170 etent patients were significantly older than immunocompromised patients (73 vs. 48.6 years, p < 0.000

171 ed antigenemia in HIV-positive than non-HIV, immunocompromised patients (P < 0.001).

172 ividuals or a serious, systemic infection in immunocompromised patients and has a global impact.

173 py for human adenovirus (HAdV) infections in immunocompromised patients and healthy individuals with

174 ngles), while HCMV causes serious disease in immunocompromised patients and neonates.

175 sease in a substantial proportion of non-HIV immunocompromised patients and should prompt careful cli

176 Immunocompromised patients are more susceptible to recur

177 cant morbidity and mortality worldwide, with immunocompromised patients being at particularly high ri

178 Chronic norovirus infection in immunocompromised patients can be severe, and presently

179 alence, risk factors, and characteristics of immunocompromised patients coming from the community wit

180 Immunocompromised patients experience a high incidence o

181 Immunocompromised patients generally had a delayed antib

182 poietic cell transplant, and among survivors immunocompromised patients have shorter median PICU leng

183 ive way of combating severe viral disease in immunocompromised patients in multiple phase 1 and 2 cli

184 during their storage, and cause mortality in immunocompromised patients in numbers that rival the dea

185 Recurrence of C. difficile infections among immunocompromised patients is also high, with rates up t

186 Immunocompromised patients might require combined and pr

187 ble and possible categories are proposed for immunocompromised patients only, except for endemic myco

188 tinal lymphatic transport of cannabinoids in immunocompromised patients requires caution.

189 fungi that cause opportunistic infections in immunocompromised patients since these microbes are not

190 treatment of adenovirus (HAdV) infections in immunocompromised patients still poses great challenges.

191 This is relevant especially for immunocompromised patients such as LTx-recipients or pat

192 be a major cause of death in this population Immunocompromised patients who are recipients of a solid

193 and active viral infection, particularly in immunocompromised patients who have frequent HHV-6B reac

194 r early treatment of SARS-CoV-2 infection in immunocompromised patients with blood disorders or after

195 Immunocompromised patients with hypoxemic acute respirat

196 deep-sequence longitudinal samples from four immunocompromised patients with long-term H3N2 influenza

197 The correct management of immunocompromised patients with pneumonia is debated.

198 1% of asymptomatic adults, but up to 30% of immunocompromised patients with respiratory disease.

199 update on the current knowledge of sepsis in immunocompromised patients without human immunodeficienc

200 atory infections in children and elderly and immunocompromised patients worldwide.

201 here were 10,316 (43.0%) immunosuppressed or immunocompromised patients, 4,135 (20.3%) with central l

202 use of viral diarrhea worldwide in children, immunocompromised patients, and the elderly.

203 bacterium frequently isolated from infected immunocompromised patients, and the strains are resistan

204 Plasma mNGS demonstrated higher utility for immunocompromised patients, but given the detection of m

205 lity was observed in immunocompetent than in immunocompromised patients, but this could be due to mor

206 Among immunocompromised patients, community-acquired pneumonia

207 in infants and an opportunistic infection in immunocompromised patients, Cryptosporidium research has

208 Slowly or nonresolving LD may occur in immunocompromised patients, possibly leading to lung abs

209 clinical pertinence not being established in immunocompromised patients, scarcity of clarity on the o

210 The disease impacts most severely immunocompromised patients, the elderly, and children.

211 This is particularly true in immunocompromised patients, where the damage to the micr

212 r longer treatment duration may be needed in immunocompromised patients.

213 igh morbidity and mortality, particularly in immunocompromised patients.

214 amous cell carcinomas (cSCCs) in a subset of immunocompromised patients.

215 ally infected children and severe disease in immunocompromised patients.

216 o serious health consequences in neonatal or immunocompromised patients.

217 ruses (gammaHV) can cause lymphomagenesis in immunocompromised patients.

218 mpact on clinical outcomes in transplant and immunocompromised patients.

219 le of causing severe disease in neonates and immunocompromised patients.

220 t to transplant centers and those caring for immunocompromised patients.

221 cases (5%) involving clinically unstable or immunocompromised patients.

222 of herpes simplex virus (HSV) infections in immunocompromised patients.

223 mmon cause of invasive aspergillosis (IA) in immunocompromised patients.

224 uconazole (ISA) are increasingly utilized in immunocompromised patients.

225 annually, and are typically associated with immunocompromised patients.

226 re to estimate HZ risk in five categories of immunocompromised patients.

227 increased risk of morbidity and mortality in immunocompromised patients.

228 lead to severe complications, especially in immunocompromised patients.

229 mportant opportunistic systematic mycosis in immunocompromised patients.

230 nts of severe opportunistic infections among immunocompromised patients.

231 ns such as pregnant and postpartum women and immunocompromised patients.

232 ar concern, chronic progressive hepatitis in immunocompromised patients.

233 on in kidney transplant recipients and other immunocompromised patients.

234 , is a risk factor for invasive infection in immunocompromised patients.

235 f norovirus-positive EECs in the other three immunocompromised patients.

236 ribing empiric antibiotic therapy for CAP in immunocompromised patients.

237 i remains an important cause of pneumonia in immunocompromised patients.

238 fungal pathogen that can cause infections in immunocompromised patients.

239 bolic or malignant diseases, particularly in immunocompromised patients.

240 s, particularly affecting critically ill and immunocompromised patients.

241 Antibiotic treatment is strongly advised in immunocompromised patients.

242 or the evaluation of pulmonary infections in immunocompromised patients.

243 and sepsis in newborns, pregnant women, and immunocompromised patients.

244 literature review to estimate the HZ risk in immunocompromised patients.

245 tropism of norovirus in specimens from four immunocompromised patients.

246 ns, and septicemia, in otherwise healthy and immunocompromised patients.

247 eatening invasive infections particularly in immunocompromised patients.

248 on of viruses in both previously healthy and immunocompromised patients.

249 plasmosis or postnatally acquired disease in immunocompromised patients.

250 ly skin infections and arthritis in severely immunocompromised patients.

251 astroenteritis in children, the elderly, and immunocompromised patients; some virus strains have also

252 vel population of largely non-critically ill immunocompromised pediatric patients, and attempted to s

253 cal deterioration and 28-day mortality among immunocompromised pediatric patients.

254 tion and subsequent bloodstream infection in immunocompromised pediatric patients.

255 appropriate in our previously healthy and/or immunocompromised pediatric patients.

256 V infection can be especially problematic in immunocompromised people and infants, where the virus ha

257 (HCMV) causes severe disease in infants and immunocompromised people.

258 is ineffective in malnourished children and immunocompromised people.

259 is ineffective in malnourished children and immunocompromised people.

260 dividuals, can cause severe complications in immunocompromised persons and during pregnancy.

261 ains unclear whether CMV viremia in severely immunocompromised persons with cryptococcal meningitis c

262 ains unclear whether CMV viremia in severely immunocompromised persons with cryptococcal meningitis c

263 nd in histopathology, by primarily affecting immunocompromised persons, and in a geographic range tha

264 that resistant HSV-1 is transmissible among immunocompromised persons.

265 d in both previously healthy individuals and immunocompromised persons.Among the 30-day survivors of

266 hogenesis of S. stercoralis infection in the immunocompromised population at high risk of severe stro

267 piratory tract infection in children and the immunocompromised population, but its clinical manifesta

268 seen in hospital or emergency department) in immunocompromised populations and compare it to immunoco

269 in hospital or emergency department [ED]) in immunocompromised populations and compare it to immunoco

270 ncidence of HZ complications and severity in immunocompromised populations are needed to inform econo

271 d HZ and related complications was higher in immunocompromised populations compared with immunocompet

272 d HZ and related complications was higher in immunocompromised populations compared with immunocompet

273 ce of HZ complications and their severity in immunocompromised populations is needed to inform econom

274 n incidence in conjunction with increases in immunocompromised populations or conditions that contrib

275 HZ was common among all immunocompromised populations studied, exceeding the exp

276 HZ is common among all immunocompromised populations studied-exceeding expected

277 beta-HPVs contribute to cSCC development in immunocompromised populations.

278 oster, a major health issue in the aging and immunocompromised populations.

279 dences that varied widely within and between immunocompromised populations.

280 ence, which varied widely within and between immunocompromised populations.

281 pecially in the very young, the elderly, and immunocompromised populations.

282 RICD following cranial irradiation using an immunocompromised rodent model.

283 enerated by introducing human skin grafts to immunocompromised rodent strains.

284 nduce significant infection even in severely immunocompromised- SCID or inducible NO synthase-, CD40-

285 ia coli, leading to the complete recovery of immunocompromised septic mice.

286 sociated with chronic medical conditions and immunocompromised states among infants; however, 1 in 5

287 , ICU placement, tracheostomy-dependence and immunocompromised status (90-day multivariable adjusted

288 unit placement, tracheostomy dependence, and immunocompromised status (90-day multivariable adjusted

289 est quartile than children without, while an immunocompromised status had no effect.

290 The advances in care for patients with an immunocompromised status have been remarkable over the l

291 Immunocompromised status was the only patient characteri

292 The model for the full cohort included immunocompromised status, Pediatric Logistic Organ Dysfu

293 lculated IRs and IRRs of HZ complications by immunocompromised status.

294 CMV) infection is common among patients with immunocompromised status; however, data specific to GI-C

295 modelling, the development of a genetically immunocompromised strain for xenotransplantation of huma

296 in bronchoalveolar lavage fluid (BALF) from immunocompromised subjects with lower respiratory tract

297 VID-19) pandemic poses special challenges to immunocompromised transplant patients.

298 enty-three patients (56 immunocompetent, 117 immunocompromised) were included.

299 col provides a comprehensive guide for using immunocompromised zebrafish for xenograft cell transplan

300 lt casper-strain prkdc(-/-), il2rgalpha(-/-) immunocompromised zebrafish that robustly engraft human